Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
NCT05158140
Completed
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/11/2024
Locations: Benchmark Research ( Site 0007), Austin, Texas +8 locations
Conditions: Pneumococcal Infection
Register for Updates
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2024
Locations: AES - DRS - Optimal Research Texas - Austin, Austin, Texas +21 locations
Conditions: SARS-CoV-2, Influenza
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
NCT05975060
Completed
This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ in previously mRNA COVID-19 vaccinated adult participants ≥18 years of age and baseline SARS CoV-2 seropositive COVID-19 vaccine naïve participants ≥18 years of age.
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
05/29/2024
Locations: Benchmark Research, Austin, Texas +6 locations
Conditions: COVID-19
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
NCT03615482
Completed
This study was designed to evaluate the safety and tolerability of a single dose of V114 when administered concomitantly and non-concomitantly (i.e., 30 days after) with influenza vaccine. It also evaluated whether V114 can be administered concomitantly with influenza vaccine without impairing the antibody response to the 15 serotypes contained in V114 and to the 4 influenza viruses contained in the seasonal inactivated quadrivalent influenza vaccine (QIV). The primary hypotheses state that immu... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/20/2024
Locations: Wellness Clinical Research Associates ( Site 0048), Allen, Texas +3 locations
Conditions: Pneumococcal Infections
Register for Updates
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
NCT04766086
Completed
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/25/2024
Locations: Benchmark Research, Fort Worth, Texas +1 locations
Conditions: Group B Streptococcus Infections
Register for Updates
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522
Completed
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Elligo Clinical Research Center, Austin, Texas +36 locations
Conditions: Influenza, Human
Register for Updates
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/01/2024
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Register for Updates
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
NCT03739112
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 206) Benchmark Research, Austin, Texas +5 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
NCT01964989
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 208, Novartis Investigational Site, Austin, Texas +5 locations
Conditions: Influenza Virus
Register for Updates
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
NCT02255409
Completed
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
Gender:
ALL
Ages:
Between 12 months and 84 months
Trial Updated:
03/06/2023
Locations: Not set, Austin, Texas +3 locations
Conditions: Influenza
Register for Updates
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
NCT03620162
Completed
The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV immunization schedule.
Gender:
ALL
Ages:
Between 42 days and 90 days
Trial Updated:
01/12/2023
Locations: Ventavia Research Group LLC ( Site 0017), Fort Worth, Texas +1 locations
Conditions: Pneumococcal Infections
Register for Updates
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590
Completed
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years. As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2022
Locations: GSK Investigational Site, Fort Worth, Texas +2 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates